New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 5 of 8
HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment
NCT01383837
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
NCT01173874
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
NCT01748955
Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
NCT01783080
Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients
NCT01134198
Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders
NCT01104805
Enhancing Attention in Adults With Compulsive Hoarding
NCT01100268
Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)
NCT01100255
Training Clinicians in Motivational Interviewing
NCT01065480
A Study of Medication With or Without Psychotherapy for Complicated Grief
NCT01179568
Exercise and Inflammation
NCT01335737
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
NCT01919216
Dronabinol Naltrexone Treatment for Opioid Dependence
NCT01024335
Combined Pharmacotherapy for Cannabis Dependency
NCT01020019
Psychological Symptoms Among Adolescents Enrolled in a Bariatric Surgery Program
NCT01079377
Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression
NCT01922219
Inpatient Exposure Therapy and Response Prevention & Cognitive Remediation Therapy for Anorexia Nervosa
NCT01174602
PET Biomarkers in Treatment Resistant Depression
NCT01031810
Interpersonal Therapy for Depression in Breast Cancer
NCT01191580
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
NCT00956085
Cognitive-Motivational Behavior Therapy for Pathological Gamblers
NCT01135264
Study of Quetiapine Treatment for Cannabis Dependence
NCT00954681
Examining Common Substrates of Eating and Alcohol Use Disorders
NCT01172210
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
NCT01760473
Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
NCT00834834
Modafinil for Smoked Cocaine Self-Administration
NCT01778010
Characteristics and Importance of Physical Activity in Women With Anorexia Nervosa
NCT00917423
Studying the Effects of Sibutramine on Eating Behavior
NCT01170364
The Efficacy of Parent Involvement in the Treatment of Adolescent Depression
NCT00883519
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
NCT01754493
Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy
NCT00791440
Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism
NCT01983189
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
NCT00723177
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
NCT01172873
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
NCT00742573
Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)
NCT00728923
Effect of Quetiapine on Marijuana Withdrawal and Relapse
NCT00743366
Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa
NCT00670293
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
NCT00743119
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
NCT00737204
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
NCT00476242
Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
NCT00743145
Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder
NCT00739765
Study of Interpersonal Therapy and Complicated Grief Treatment in Adults 50 Years and Older
NCT01244295
The Development of an Eating Laboratory for Overweight Adolescents
NCT00764127
Progesterone Treatment for Cocaine-dependent Women: A Pilot Study
NCT00632099
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
NCT00564278
Effects of Varenicline on Cigarette Self Administration
NCT00731055
Cognitive Behavioral Therapy for Adolescents With Bulimia
NCT00755391
Food Exposure Therapy in Anorexia Nervosa
NCT00755820
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.